Darya-Varia Laboratoria Tbk PT
IDX:DVLA
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1 390
1 810
|
| Price Target |
|
We'll email you a reminder when the closing price reaches IDR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Darya-Varia Laboratoria Tbk PT
Darya-Varia Laboratoria Tbk PT
Cash
Darya-Varia Laboratoria Tbk PT
Cash Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Darya-Varia Laboratoria Tbk PT
IDX:DVLA
|
Cash
Rp437.9B
|
CAGR 3-Years
14%
|
CAGR 5-Years
42%
|
CAGR 10-Years
26%
|
|
|
T
|
Tempo Scan Pacific Tbk PT
IDX:TSPC
|
Cash
Rp64.6B
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
23%
|
|
|
Kalbe Farma Tbk PT
IDX:KLBF
|
Cash
Rp1.6T
|
CAGR 3-Years
-16%
|
CAGR 5-Years
9%
|
CAGR 10-Years
13%
|
|
|
Soho Global Health Tbk PT
IDX:SOHO
|
Cash
Rp470.5B
|
CAGR 3-Years
21%
|
CAGR 5-Years
35%
|
CAGR 10-Years
N/A
|
|
|
Pyridam Farma Tbk PT
IDX:PYFA
|
Cash
Rp505.4B
|
CAGR 3-Years
129%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
70%
|
|
|
Kimia Farma Tbk PT
IDX:KAEF
|
Cash
Rp504.7B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
0%
|
CAGR 10-Years
13%
|
|
Darya-Varia Laboratoria Tbk PT
Glance View
PT Darya-Varia Laboratoria Tbk engages in the manufacture and trade of pharmaceutical products and cosmetics. The company is headquartered in Jakarta, Dki Jakarta and currently employs 1,274 full-time employees. Its segments include prescription drugs, consumer health products, and export and toll manufacturing services. The firm provides products and services for consumer health, skin nutrition, respiratory, vitamins and daily relief. The Company’s products include Remscar (silicone gel), Carvilol, Ondavar (antiemetic), Etorix, Forti-D (vitamin D supplement), Decolgen, Neozep, Stop Cold, Decolsin, and Allerin. The Carvilol is used for heart health and treating hypertension. Ondavar is an antiemetic product used for nausea and vomiting during pregnancy. Etorix is a pain reliever. Forti-D is a supplement to fulfill the body’s need for vitamin D3. Darya-Varia provides a range of brands such as Enervon-C, Enervon Active, and Supertin that helps to boost body immune and maintain health. The firm also provides Imunped as supplement for kids with Zinc and vitamin C for children.
See Also
What is Darya-Varia Laboratoria Tbk PT's Cash?
Cash
437.9B
IDR
Based on the financial report for Sep 30, 2024, Darya-Varia Laboratoria Tbk PT's Cash amounts to 437.9B IDR.
What is Darya-Varia Laboratoria Tbk PT's Cash growth rate?
Cash CAGR 10Y
26%
Over the last year, the Cash growth was 53%. The average annual Cash growth rates for Darya-Varia Laboratoria Tbk PT have been 14% over the past three years , 42% over the past five years , and 26% over the past ten years .
You don't have any saved screeners yet
